ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS SCIE Q1Scopus Q1SCImago #435Top JournalReview JournalHybrid

Advanced Drug Delivery Reviews

Acronym:addr
•
Abbreviation (ISO):ADV. DRUG DELIVERY REV
•
Identifier (ISSN):0169-409X(Print)/1872-8294(Online)
•
Publisher:Elsevier
Clarivate IF (2026)
21↑ +3.4
Journal Impact Factor
IF Trend↓
WoS Quartile
Q1
WoS SCIETop Tier
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Advanced Drug Delivery Reviews

WoS Q1
915212713.7201815.5201913.3202015.5202117.9202216.1202315.2202417.6202521.02026
Annual Impact Factor Metric
Current (2026):21
Scopus SJR & RankScopus Q1
4.015
#435

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
405

405 papers with at least that number of citations each

WoS: SCIE / JCRTop Tier
Self-Citation Rate3.9%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
312articles/year
30.83% Gold OA•0% Original Research

Aims & Scope

The aim of the Journal is to provide a forum for the critical analysis of advanced drug and gene delivery systems and their applications in human and veterinary medicine. The Journal has a broad scope, covering the key issues for effective drug and gene delivery, from administration to site-specific delivery. In general, the Journal publishes review articles in a Theme Issue format. Each Theme Issue provides a comprehensive and critical examination of current and emerging research on the design and development of advanced drug and gene delivery systems and their application to experimental and clinical therapeutics. The goal is to illustrate the pivotal role of a multidisciplinary approach to modern drug delivery, encompassing the application of sound biological and physicochemical principles to the engineering of drug delivery systems to meet the therapeutic need at hand. Importantly the Editorial Team of ADDR asks that the authors effectively window the extensive volume of literature, pick the important contributions and explain their importance, produce a forward looking identification of the challenges facing the field and produce a Conclusions section with expert recommendations to address the issues. Articles review the current status of a specific topic, giving equal emphasis to the identification of major conceptual and technological challenges to successful drug and gene delivery, to an evaluation of triumphs as well as shortcomings in current conceptual and technical approaches, and to a discussion of their possible solution.

Topics Covered (Recognized by AI)
Biology84.6%Chemistry84.5%Medicine80.1%Genetics61.5%Biochemistry56.2%Materials science49.1%Organic chemistry47.8%Internal medicine45.1%Nanotechnology44.8%Pharmacology41.8%Psychology37.9%Physics37.1%Engineering35%Psychiatry32.4%Drug delivery31.2%Drug28%Gene23%Immunology22.3%Cell biology21.8%Pathology21.5%
Primary Research Areas

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRSCIE2026

PHARMACOLOGY & PHARMACY

Q1
Rank4/356
IndexSCIE
JCISCIE2026

PHARMACOLOGY & PHARMACY

Q1
Rank9/356
IndexSCIE

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF21
Articles / Year120
Total Citations227
2025
IF17.6
Articles / Year147
Total Citations1,774
2024
IF15.2
Articles / Year137
Total Citations4,315
2023
IF16.1
Articles / Year206
Total Citations11,790
2022
IF17.873
Articles / Year278
Total Citations19,300

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #435Scopus Q1SCImago Profile
Scopus Coverage:1987-2026
Scopus Broad Areas:Pharmacology, Toxicology and Pharmaceutics
Scopus Citation Rank (SJR)Q1
4.015

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1
Citations / Doc (2 years)
20.34

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$4,175 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations12,320
3-Year Documents594
Citable Documents551

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate45.7%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Pharmaceutical ScienceQ1
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 3.9%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
1区 (Zone 1)Medicine
Minor Category (Specific Field):
1区PHARMACOLOGY & PHARMACY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Advanced Drug Delivery Reviews (acronym: addr, abbr: ADV. DRUG DELIVERY REV, ISSN: 0169-409X) is a peer-reviewed international scholarly journal in the field of Medicine, published by Elsevier in Netherlands since 1987. The periodical holds a Journal Impact Factor (JIF) of 21.0, ranking in quartile Q1 of Web of Science (SCIE), a Scopus SJR indicator of 4.015 (Q1), an H-index of 405.

The journal enforces rigorous peer evaluation with an average review speed of 15.1周, a publication frequency of Monthly, an annual output of approximately 312 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $4,175 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Hybrid
Publisher
Elsevier
Publication Language
English
Frequency
Monthly
Founding Year
1987
Indexing & Databases
SCIEScopusPubMed
Editorial Address
ELSEVIER SCIENCE BV, PO BOX 211, AMSTERDAM, NETHERLANDS, 1000 AE

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 59e57989-4800-422b-b1ab-0ee876ed4ef1
Database Updated: 2026-10-16